to assess premature inflammaging and senescence rates and new senolytic therapies?; (vii) does this work question current cancer strategies, where guidelines recommend recombinant IL11 as a supplementary treatment to avoid chemotherapy‐induced thrombocytopenia?; (viii) similarly, should the inclusion of IL11 neutralizing antibodies be considered in current immunotherapy strategies against tumorigenesis?; (ix) previous findings have shown that IL11 is pro‐inflammatory, pro‐fibrotic, and anti‐regenerative in heart, liver, lung, and kidney diseases in mice and humans. Here, IL11 is linked to kidney disorder.